Clexio Biosciences

Clexio Biosciences is excited to share that Hadile Ounallah-Saad, PhD, MBA, our Head of Innovation and Early-Stage Pipeline, will be presenting at the Innovation in Psychosis Therapeutics Summit in Boston, next week.   Hadile will be presenting “CLE-905, A Potent M1/M4 Entering First-In-Human: Similarities to Xanomeline & Targeted Differentiation from Cobenfy” on 11th June.   She will also be participating in a panel discussion: “Reframing Muscarinic Modulation: Lessons from Trials, Selectivity Challenges and the Placebo Puzzle” on 10th June.   If you are attending the conference, we look forward to meeting you there! CLE-905, is a potent M1/M4 preferential muscarinic agonist for the treatment of Schizophrenia. CLE-905 is an investigational drug that has not been previously approved for commercial distribution.     www.clexio.com #clexio #innovation #psychosis #CNS #schizophrenia #biploar

In the search for new models to enhance precision in drug development in Psychiatry, Clexio Biosciences is proud to have collaborated with NeuroKaire (formerly Genetika+) to explore the utility of NeuroKaire’s biomarker for profiling the efficacy of antidepressant compounds. The findings were presented in a poster at the #CNSSummit.   This approach was used to assess CLE-100's (parent and metabolite) effect on synaptic plasticity in iPSC-derived neurons, from individual well-characterized depressed patients.   CLE-100 is an investigational drug and is currently not approved for commercial distribution. For a look at the full poster, click: https://lnkd.in/dabt-tqe   For more information on Clexio please visit our website: www.clexio.com   #depression #MDD #CLE-100 #esketamine #CNSSummit 

We are pleased to share that we have reached 50% enrollment in the SOLEO study, a Phase 2 study assessing the safety and efficacy of CLE-100 as an adjunctive treatment in subjects with Major Depressive Disorder, who have had inadequate response to standard antidepressant therapies. The study is enrolling in the US. CLE-100 is an investigational drug and is currently not approved for commercial distribution. For more information on SOLEO, please visit: https://lnkd.in/daJA-qyC To learn more about CLE-100, visit  https://lnkd.in/d5RXyPt   #ClinicalTrials #MDD #Clexio #CNS #psychiatry #mentalhealth